Irritable Bowel Syndrome | Executive Insights | US | 2019
The irritable bowel syndrome (IBS) market has experienced slow growth owing to a lack of disease understanding, low rate of patients seeking treatment, and few effective therapies that treat all symptoms of the disease. Existing agents primarily treat motility symptoms, with few effects on pain, discomfort, and/or the underlying cause of the disease. Furthermore, development of drugs specifically indicated for the diarrhea-predominant form remains elusive. DRG anticipates a market shift over the next ten years, especially in the constipation-predominant form of IBS, with development and launch of two new therapies: tenapanor and prucalopride. Tenapanor has a novel mechanism of action, has demonstrated good clinical efficacy, and is poised to disrupt the current market by providing relief for pain symptoms, which are of greatest concern to patients.
QUESTIONS ANSWERED
What are the key areas of unmet need and opportunity in IBS and within IBS subtypes? · What is the expected impact of novel therapy launches over the next ten years, and how might these launches impact opportunities in the IBS market? · What influence does each major player hold over the IBS market? · How is the IBS market expected to change over the next ten years?
GEOGRAPHY COVERED
United States Primary Research 3 KOL interviews in October 2018
KEY COMPANIES COVERED
Allergan, Takeda, Ardelyx, Shire
KEY DRUGS COVERED
Viberzi, tenapanor, prucalopride, Linzess
